Abstract
Background Management of COVID-19 in transplant patients is a big challenge. Data on immunosuppression management, clinical picture, and outcomes are lacking.
Objectives To summarize the current literature on COVID-19 in transplant patients especially the data regarding the immunosuppression protocols, clinical presentation, and outcomes.
Search strategy A systematic search of MEDLINE, EBSCO, CENTRAL, CINAHL, LitCovid, Web of Science, and Scopus electronic databases. The references of the relevant studies were also searched. The search was last updated on June 3, 2020.
Selection Criteria Primary reports of solid organ transplant patients who developed COVID-19. An overlap of cases in different reports was checked.
Data collection and analysis A descriptive summary of immunosuppression therapy (before and after COVID-19), clinical presentation (symptoms, imaging, laboratory, and disease severity), management (oxygen therapy, antiviral, and antibacterial), major outcomes (Intensive care admission, invasive mechanical ventilation, acute kidney injury), and mortality.
Main results We identified 74 studies reporting 823 cases of solid organ transplantation with COVID-19. Among 372 patients, 114 (30.6%) were mild COVID-19, 101 (27.2%) moderate, and 157 (42.2%) severe or critical.
Major outcomes included intensive care unit admission, invasive ventilation, and acute kidney injury, which occurred in 121 (14.7%), 97 (11.8%), and 63 (7.7%) of patients, respectively. Mortality was reported in 160 (19.4%) patients. Missing individual data hindered making clinical correlations.
Conclusion COVID-19 in solid organ transplant patients probably has a more disease severity, worse major outcomes (Intensive care admission, invasive ventilation, acute kidney injury), and higher mortality than in non-transplant patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval is not relevant to this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authorship: 1. Moataz Maher Emara (MME): performed the electronic serach on the databases, screened for the relevant studies, created the data charting file, continuously updated the search results, collated the data from the all data collectors, and wrote the primary manuscript.
2. Mahmoud Elsedeiq (MEs): screened for the relevant studies, independently collected data from the selected studies, approved and revised the final manuscript.
3. Mohamed Elmorshedi (MEm): continuously updated the data collection from the continuously added studies, helped in writing the manuscript, approved and revised the final manuscript.
4. Hamed Neamatallah (HN): screened for the relevant studies, independently collected data from the selected studies, approved and revised the final manuscript.
5. Mostafa Abdelkhalek (MA): continuously updated the data collection from the continuously added studies, approved and revised the final manuscript.
6. Amr Yassen (AY): guided the search and writing of the manuscript.
7. Ashraf Nabhan (AN): guided the search and writing of the manuscript.
All authors participated conceptually in the study, revised, and accepted the final manuscript.
Disclosure and funding: The authors declare no conflicts of interest and did not receive any financial support.
Data Availability
Data will be available on request.
Abbreviations
- AKI
- Acute Kidney Injury
- ARDS
- Acute Respiratory Distress Syndrome
- CNI
- Calcineurine inhibitor
- CRP
- C-reactive protein
- CT
- Computed Tomography
- ECMO
- Extracorporeal Membrane Oxygenation
- ICU
- Intensive Care Unit
- LDH
- Lactate Dehydrogenase
- mTORi
- mammalian Target Organ of Rapamycin inhibitor
- MV
- Mechanical Ventilation
- MMF
- Mycophenolate Mofetil
- PRISMA
- Preferred Reporting Items for Systematic Review and Meta-Analysis
- rt-PCR
- reverse transcription – Polymerase Chain Reaction
- SARS-CoV-2
- severe acute respiratory syndrome – coronavirus-2
